Literature DB >> 4148104

Letter: Hemolytic anemia as adverse reaction to salicylazosulfapyridine.

E P Gabor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4148104     DOI： 10.1056/NEJM197312202892514

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.

Authors:  R E Pounder; E R Craven; J S Henthorn; J M Bannatyne
Journal:  Gut       Date:  1975-03       Impact factor: 23.059

Review 2.  Sulfasalazine. Adverse effects and desensitization.

Authors:  S L Taffet; K M Das
Journal:  Dig Dis Sci       Date:  1983-09       Impact factor: 3.199

Review 3.  Comparative tolerability of therapies for ulcerative colitis.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

Authors:  A K Azad Khan; D T Howes; J Piris; S C Truelove
Journal:  Gut       Date:  1980-03       Impact factor: 23.059
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.